Dr. Tauseef Ali, M.D.

Medicare patients and services

Medicare patients, 2024

449

Services billed

903

Patients’ average age

70

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 69 payments worth $92,558 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Oklahoma →

Industry-funded research

Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $407,854 in research payments for these studies, mostly to the institutions running them.

• A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
  AbbVie Inc. · Active, not recruiting · NCT06063967
• M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease
  AbbVie Inc.
• Roche Cancer Screening Collection Study
  Genentech, Inc.
• A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
  Ferring Pharmaceuticals As
• A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to …
  Takeda Pharmaceuticals U.S.A., Inc.
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
  Takeda Pharmaceuticals U.S.A., Inc. · Active, not recruiting · NCT06254950
• A multicenter prospective noninterventional study of realworld effectiveness of etrasimod in patients with ulcerative colitis endeavouruc
  Pfizer Inc.
• A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerat…
  Amgen Inc.
• A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis
  Takeda Pharmaceuticals U.S.A., Inc.
• M20-259 - Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD)
  AbbVie Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Gastroenterology clinicians in Oklahoma City

• Jean Abed, M.D.
• Ahmed Abdelsatar Ali Abomhya
• Ahmad Al-taee, M.D.
• Ijlal Akbar Ali, MD
• Teddy F. Bader, MD
• Romelia A. Barba Bernal, MD
• Hussein Bitar, MD
• Deborah S. Blalock, MD